ARTICLE | Emerging Company Profile

Mestag: Attacking tumors from within

Immunology company’s lead program targets a specific fibroblast subpopulation to induce formation of tertiary lymphoid structures in solid tumors

July 10, 2024 11:28 PM UTC

Immunology company Mestag believes that fibroblasts have been long overlooked as therapeutic targets and can be leveraged to treat cancer and inflammatory diseases. The company has raised $45 million and presented data for its lead program to treat solid tumors at AACR. 

CEO Susan Hill told BioCentury that Cambridge, U.K.-basaed Mestag Therapeutics Ltd. was founded by a group of five scientists who had identified a distinct subpopulation of fibroblasts capable of inducing the formation of tertiary lymphoid structures (TLSs) — vascularized hubs of lymphocyte interaction and activation that arise from interactions between activated T and B cells and cytokines  CCL19, CCL21 and CXCL13. ...